CEO August Troendle highlighted that the current quarter saw cancellations rise again, with backlog cancellations reaching their highest point in over a year.
Most of the cancellations in the quarter were oncology and cardiovascular.
In an investor call, the CEO said that the cancellations remain elevated across both backlog and pre-backlog, creating near-term revenue pressure.
Sequential growth is expected to be flat, as reflected in the first quarter versus the rest of the year, though year-over-year growth should still hold.
Visibility beyond the next two quarters is limited, and management is not yet in a position to assess 2027.
Overall, the near-term growth trajectory — both now and over the next six months — remains uncertain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.